Hope for youngest HAE patients: daily pill aims to stop dangerous swelling
NCT ID NCT05453968
Summary
This study is testing a daily oral medication called berotralstat to prevent painful and dangerous swelling attacks in children aged 2 to 12 with hereditary angioedema (HAE). Researchers are finding the right dose based on a child's weight and checking how safe the drug is for young patients. The goal is to give children a long-term treatment option to control their condition and reduce the number of attacks they experience.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigative Site #1
Vienna, Ontario, Austria
-
Investigative Site #1
Ottawa, Ontario, Canada
-
Investigative Site #1
Paris, France
-
Investigative Site #1
Berlin, Germany
-
Investigative Site #1
Tel Aviv, Israel
-
Investigative Site #1
Padua, Italy
-
Investigative Site #1
Krakow, Poland
-
Investigative Site #1
Sângeorgiu de Mureş, Romania
-
Investigative Site #1
Madrid, Spain
-
Investigative Site #1
Bristol, United Kingdom
-
Investigative Site #2
Marseille, France
-
Investigative Site #2
Frankfurt, Germany
-
Investigative Site #2
Haifa, Israel
-
Investigative Site #2
Málaga, Spain
-
Investigative Site #3
Grenoble, France
Conditions
Explore the condition pages connected to this study.